← All trials
NCT04901117
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Aug 31, 2023
- First posted
- May 25, 2021
- Last posted
- May 25, 2021
- Enrollment
- 1300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shandong UniversityLead sponsor
- Tai'an Central HospitalCollaborator
- Shandong UniversityOverall official - principal investigator
- Shandong UniversityCollaborator
- Shandong UniversityReponsible party - principal investigator
- Qingdao UniversityCollaborator
- Weifang People's HospitalCollaborator
- Weihai Municipal HospitalCollaborator
- PKUcare luzhong hospitalCollaborator
- Zoucheng People's HospitalCollaborator
- Yuncheng Chengxin HospitalCollaborator
- Heze Municipal 3rd people's hospitalCollaborator
- Jining No.2 People's HospitalCollaborator
- Qihe County City HospitalCollaborator
- The People's Hospital of GuangraoCollaborator
- Maternity and Child Care Health Center of DezhouCollaborator
- Shandong Electric Power Central HospitalCollaborator
- Shandong Provincial Third HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.